LAVA Therapeutics N.V.
LVTX
$1.62
$0.010.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -37.35% | -23.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -38.21% | -7.31% | |||
| Operating Income | 38.21% | -137.42% | |||
| Income Before Tax | -163.28% | 9.36% | |||
| Income Tax Expenses | -68.00% | -40.79% | |||
| Earnings from Continuing Operations | -148.32% | 12.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -148.32% | 12.37% | |||
| EBIT | 38.21% | -137.42% | |||
| EBITDA | 37.43% | -140.62% | |||
| EPS Basic | -148.22% | 12.45% | |||
| Normalized Basic EPS | 29.47% | -2,829.17% | |||
| EPS Diluted | -148.22% | 12.45% | |||
| Normalized Diluted EPS | 29.47% | -2,829.17% | |||
| Average Basic Shares Outstanding | 0.02% | 0.10% | |||
| Average Diluted Shares Outstanding | 0.02% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||